137 related articles for article (PubMed ID: 25272370)
41. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
Brouwers J; Tack J; Augustijns P
Pharm Res; 2007 Oct; 24(10):1862-9. PubMed ID: 17443397
[TBL] [Abstract][Full Text] [Related]
42. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
Sadler BM; Piliero PJ; Preston SL; Lloyd PP; Lou Y; Stein DS
AIDS; 2001 May; 15(8):1009-18. PubMed ID: 11399983
[TBL] [Abstract][Full Text] [Related]
44. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
Pellegrin I; Breilh D; Coureau G; Boucher S; Neau D; Merel P; Lacoste D; Fleury H; Saux MC; Pellegrin JL; Lazaro E; Dabis F; Thiébaut R;
Antimicrob Agents Chemother; 2007 Apr; 51(4):1473-80. PubMed ID: 17296739
[TBL] [Abstract][Full Text] [Related]
45. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
46. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Dailly E; Raffi F; Biron C; Allavena C; Jolliet P
Fundam Clin Pharmacol; 2008 Feb; 22(1):101-4. PubMed ID: 18251726
[TBL] [Abstract][Full Text] [Related]
47. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Eke AC; Wang J; Amin K; Shapiro DE; Stek A; Smith E; Chakhtoura N; Basar M; George K; Knapp KM; João EC; Rungruengthanakit K; Capparelli E; Burchett S; Mirochnick M; Best BM;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015036
[TBL] [Abstract][Full Text] [Related]
48. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
[TBL] [Abstract][Full Text] [Related]
49. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
[TBL] [Abstract][Full Text] [Related]
50. Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.
Nasta P; Salmon D; d'Arminio Monforte A; Pimenta JM; Cerini C; Giralda M; Winnock M; Cozzi-Lepri A
HIV Clin Trials; 2016 May; 17(3):96-108. PubMed ID: 27125364
[TBL] [Abstract][Full Text] [Related]
51. [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
Delgado O; Riera M; Murillas J; Ventayol P
Enferm Infecc Microbiol Clin; 2008 Mar; 26(3):182-3. PubMed ID: 18358222
[No Abstract] [Full Text] [Related]
52. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients.
Wood R; Gathe JC; Givens N; Sedani S; Cheng K; Sievers J
HIV Clin Trials; 2013; 14(5):183-91. PubMed ID: 24144895
[TBL] [Abstract][Full Text] [Related]
53. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
Wire MB; Ballow C; Preston SL; Hendrix CW; Piliero PJ; Lou Y; Stein DS
AIDS; 2004 Apr; 18(6):897-907. PubMed ID: 15060437
[TBL] [Abstract][Full Text] [Related]
55. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
56. Clinical pharmacology and pharmacokinetics of amprenavir.
Sadler BM; Stein DS
Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
[TBL] [Abstract][Full Text] [Related]
57. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
[TBL] [Abstract][Full Text] [Related]
58. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens.
Pineda JA; Pérez-Elías MJ; Peña JM; Luque I; Rodríguez-Alcantara F;
HIV Clin Trials; 2008; 9(5):309-13. PubMed ID: 18977719
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
[TBL] [Abstract][Full Text] [Related]
60. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]